| Literature DB >> 30661664 |
Chelsea Luther1, Umang Swami2, Jun Zhang2, Mohammed Milhem2, Yousef Zakharia3.
Abstract
Metastatic melanoma therapies have proliferated over the last ten years. Prior to this, decades passed with only very few drugs available to offer our patients, and even then, those few drugs had minimal survival benefits. Many treatment options emerged over the last ten years with diverse mechanisms of action. Further, combination regimens have demonstrated superiority over monotherapy, especially for targeted agents. Each therapeutic combination possesses different advantages and side effect profiles. In this review, we outline the United States Food and Drug Administration-approved melanoma treatment agents and therapies currently in clinical development, focusing on combination approaches.Entities:
Keywords: BRAF; CTLA-4; Combination therapy; Dabrafenib; Epacadostat; Immunotherapy; Indoleamine 2,3-dioxygenase; Indoximod (D-1MT); Ipilimumab; MEDI4736; Metastatic melanoma; Nivolumab; PD1; Pembrolizumab; TVEC; Talimogene; Targeted therapy; Vemurafenib
Mesh：
Substances：
Year: 2018 PMID： 30661664 DOI： 10.1016/j.critrevonc.2018.11.002
Source DB: PubMed Journal: Crit Rev Oncol Hematol ISSN： 1040-8428 Impact factor: 6.312